ReviewBJOG : an international journal of obstetrics and gynaecology2018
Angiogenic factors: potential to change clinical practice in pre-eclampsia?
Review in BJOG : an international journal of obstetrics and gynaecology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 74 citations in OpenAlex.
- sFlt-1/PlGF Ratio as a Central Biomarker for Preeclampsia and Perinatal Outcomes: A Multisystem Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- PRESHA - Preventing severe hypertensive adverse events in pregnancy and childbirth: a study protocol for establishing a prospective cohort study and biobank in urban Tanzania.Frontiers in global women's health · 2026Article
- Increase of augmentation index (AIx@75): a promising tool for screening hypertensive pregnancy disorders.BMC pregnancy and childbirth · 2025Article
- Association of phthalates exposure and sex steroid hormones with late-onset preeclampsia: a case-control study.BMC pregnancy and childbirth · 2024Article
- CircHIPK3/miR-124 affects angiogenesis in early-onset preeclampsia via CPT1A-mediated fatty acid oxidation.Journal of molecular medicine (Berlin, Germany) · 2024Article
- Preeclampsia at term: evidence of disease heterogeneity based on the profile of circulating cytokines and angiogenic factors.American journal of obstetrics and gynecology · 2024Article
- One-third of patients with eclampsia at term do not have an abnormal angiogenic profile.Journal of perinatal medicine · 2023Article
- VASCULAR AND RENAL MECHANISMS OF PREECLAMPSIA.Current opinion in physiology · 2023Article
- Assessment of CA-125 First-Trimester Values as a Potential Screening Marker for Pre-Eclampsia.Medicina (Kaunas, Lithuania) · 2023Observational
- Preeclampsia and aspirin.Obstetrics & gynecology science · 2023Article
- The role of immune cells and mediators in preeclampsia.Nature reviews. Nephrology · 2023Review
- HIPK2 in Angiogenesis: A Promising Biomarker in Cancer Progression and in Angiogenic Diseases.Cancers · 2023Review
- Editorial: Advances and perspectives in neuroplacentology.Frontiers in endocrinology · 2023Article
- The effectiveness of the Congo Red Dot paper test in hypertensive disorders of pregnancy: A systematic review and meta-analysis.Frontiers in reproductive health · 2023Review
- Comparison of maternal serum NRG-4 levels in healthy and preeclamptic pregnanciesJournal of the Turkish German Gynecological Association · 2022Article
- Overexpression of microRNA-100-5p attenuates the endothelial cell dysfunction by targeting HIPK2 under hypoxia and reoxygenation treatment.Journal of molecular histology · 2021Article
- Plasma fibulin-1 levels during pregnancy and delivery: a longitudinal observational study.BMC pregnancy and childbirth · 2021Observational
- Angiogenic factors and prediction for ischemic placental disease in future pregnancies.Pregnancy hypertension · 2021Article
- Unravelling the potential of angiogenic factors for the early prediction of preeclampsia.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Review
- Complement and coagulation cascades activation is the main pathophysiological pathway in early-onset severe preeclampsia revealed by maternal proteomics.Scientific reports · 2021Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Pre-eclampsia is a complex disease with significant maternal and fetal morbidity and mortality. Its syndromic nature makes diagnosis and management difficult. The field is rapidly evolving with the definition of pre-eclampsia being challenged by some organisations, with proteinuria no longer being essential in the presence of other features. In the last decade, angiogenic factors, in particular soluble fms-like tyrosine kinase 1 (sFlt-1), have emerged as important molecules in the pathogenesis of pre-eclampsia. Here we review the most recent evidence regarding the potential of these factors as biomarkers and therapeutic targets for pre-eclampsia. TWEETABLE ABSTRACT: A review of angiogenic factors, sFlt-1 and PlGF, in the diagnosis, prediction and management of pre-eclampsia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.